Nonetheless, among these proteins, PDE9A is a druggable-target, which is currently in clinical trials for Alzheimer’s disease, while FPRs have been postulated as possible targets for mitigating ischemia-induced inflammation70,71. Here, PDE9A is linked to Alzheimer disease.